Clinical Trial

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2025-02-12; most recent amendment 2026-06-30.
Trial Details
NCT Number NCT06833008
Lead Sponsor Ipsen
Conditions Advanced Solid Tumor
Enrollment 85 participants
Start Date 2025-03-14
Primary Completion 2028-10-03 (estimated)
Study Completion 2028-10-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-30